Mentari Therapeutics Announces $200 Million Private Placement For Migraine Prevention Pipeline
By Amit Chowdhry ● Yesterday at 4:24 PM
Mentari Therapeutics announced a $200 million private placement to leading healthcare investors, with proceeds intended to support continued development of its pipeline of targeted biologics for migraine prevention. The placement consisted of common stock and pre-funded warrants to purchase common stock, with investors including Fairmount, ADAR1 Capital Management, Venrock Healthcare Capital Partners, Sirenia Capital Management LP, Janus Henderson Investors, Blackstone Multi-Asset Investing, RTW Investments, Deep Track Capital, Vivo Capital, Commodore Capital, and BB Biotech, among other healthcare investors.